Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...